• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

普芦卡必利治疗慢性特发性便秘的疗效：伴有中至重度腹胀患者的分析。

Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating.

机构信息

Massachusetts General Hospital, Boston, Massachusetts, USA.

Takeda Development Centre Americas, Inc., Lexington, Massachusetts, USA.

出版信息

Am J Gastroenterol. 2022 Jan 1;117(1):184-188. doi: 10.14309/ajg.0000000000001521.

DOI:10.14309/ajg.0000000000001521
PMID:34585675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8715996/
Abstract

INTRODUCTION

This post hoc analysis evaluated the effect of prucalopride on abdominal bloating in participants with chronic idiopathic constipation (CIC) who had moderate to very severe bloating at baseline.

METHODS

Data from 6 phase 3/4 studies of prucalopride in participants with CIC were pooled. Abdominal bloating was assessed weekly using a 5-point scale (0-4).

RESULTS

The proportion of bloating responders (≥1-point improvement in abdominal bloating score at week 12) was higher in participants treated with prucalopride (62.1%) vs placebo (49.6%).

DISCUSSION

The prucalopride arm had a higher proportion of bloating responders vs placebo in this study population.

摘要

简介

本事后分析评估了普芦卡必利对基线时存在中重度腹胀的慢性特发性便秘（CIC）患者的腹胀的影响。

方法

汇总了普芦卡必利治疗 CIC 参与者的 6 项 3/4 期研究的数据。使用 5 分制（0-4）每周评估一次腹胀。

结果

在第 12 周时，腹胀改善≥1 分的腹胀缓解者比例在普芦卡必利治疗组（62.1%）高于安慰剂组（49.6%）。

讨论

在该研究人群中，普芦卡必利组的腹胀缓解者比例高于安慰剂组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60a4/8715996/a5af63becba1/acg-117-184-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60a4/8715996/b4c3d4bbb6bc/acg-117-184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60a4/8715996/0202cca23636/acg-117-184-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60a4/8715996/a5af63becba1/acg-117-184-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60a4/8715996/b4c3d4bbb6bc/acg-117-184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60a4/8715996/0202cca23636/acg-117-184-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60a4/8715996/a5af63becba1/acg-117-184-g003.jpg

相似文献

1
Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating.普芦卡必利治疗慢性特发性便秘的疗效：伴有中至重度腹胀患者的分析。
Am J Gastroenterol. 2022 Jan 1;117(1):184-188. doi: 10.14309/ajg.0000000000001521.
2
Effect of prucalopride on symptoms of chronic constipation.普芦卡必利对慢性便秘症状的影响。
Neurogastroenterol Motil. 2014 Jan;26(1):21-7. doi: 10.1111/nmo.12217. Epub 2013 Sep 20.
3
The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.利那洛肽治疗前后，慢性特发性便秘患者腹痛对整体指标的影响：两项随机、双盲、安慰剂对照3期试验的汇总分析
Aliment Pharmacol Ther. 2014 Dec;40(11-12):1302-12. doi: 10.1111/apt.12985. Epub 2014 Oct 13.
4
Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.普芦卡必利治疗慢性非癌痛合并阿片类药物所致便秘患者的疗效和安全性。
Dig Dis Sci. 2010 Oct;55(10):2912-21. doi: 10.1007/s10620-010-1229-y. Epub 2010 Apr 30.
5
Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.普卡必利改善便秘型肠易激综合征的腹胀和肠道症状。
Dig Dis Sci. 2024 May;69(5):1731-1738. doi: 10.1007/s10620-024-08330-y. Epub 2024 Apr 9.
6
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.利那洛肽治疗中重度腹胀的慢性特发性便秘患者：一项随机对照试验
PLoS One. 2015 Jul 29;10(7):e0134349. doi: 10.1371/journal.pone.0134349. eCollection 2015.
7
Prucalopride: A Review in Chronic Idiopathic Constipation.普芦卡必利：治疗慢性特发性便秘的研究进展。
Drugs. 2016 Jan;76(1):99-110. doi: 10.1007/s40265-015-0518-3.
8
An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation.普芦卡必利治疗慢性特发性便秘的疗效和安全性概述。
Expert Opin Pharmacother. 2019 Dec;20(17):2073-2080. doi: 10.1080/14656566.2019.1668927. Epub 2019 Sep 26.
9
Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States.普芦卡必利治疗前后的临床结局：美国慢性特发性便秘患者的观察性研究。
Clin Transl Gastroenterol. 2024 May 1;15(5):e00687. doi: 10.14309/ctg.0000000000000687.
10
A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation.一项随机、双盲、安慰剂对照的3期试验，旨在评估普芦卡必利治疗慢性便秘男性患者的疗效、安全性和耐受性。
Am J Gastroenterol. 2015 May;110(5):741-8. doi: 10.1038/ajg.2015.115. Epub 2015 Apr 14.

引用本文的文献

1
Electroacupuncture versus 5-HT4 receptor agonist for functional constipation: A systematic review and meta-analysis of randomized controlled trials.电针与 5-HT4 受体激动剂治疗功能性便秘的疗效比较：一项随机对照试验的系统评价和荟萃分析。
Medicine (Baltimore). 2024 Nov 29;103(48):e40634. doi: 10.1097/MD.0000000000040634.
2
The Disease Spectrum and Natural History of Patients With Abdominal Bloating or Distension: A Longitudinal Study.腹胀或腹部膨隆患者的疾病谱与自然史：一项纵向研究
J Neurogastroenterol Motil. 2024 Jan 30;30(1):64-72. doi: 10.5056/jnm22197.
3
Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety.
普芦卡必利治疗胃轻瘫和慢性便秘的当前观点：聚焦患者选择与安全性
Ther Clin Risk Manag. 2021 Jun 8;17:601-615. doi: 10.2147/TCRM.S269330. eCollection 2021.